Symptomtext
received a dose / that was not shaken vigorously to obtain a homogeneous, turbid, white suspension; This case was reported by a pharmacist via call center representative and described the occurrence of inappropriate reconstitution technique in a 68-year-old female patient who received DTPa (Reduced antigen) (Boostrix) (batch number Z59N7, expiry date 8th October 2022) for prophylaxis. Co-suspect products included dtpa vaccine. pre-filled syringe device (Boostrix Pre-Filled Syringe Device) injection syringe (batch number Z59n7, expiry date 8th October 2022) for prophylaxis. On 21st June 2021, the patient received Boostrix and Boostrix Pre-Filled Syringe Device. On 21st June 2021, unknown after receiving Boostrix and Boostrix Pre-Filled Syringe Device, the patient experienced inappropriate reconstitution technique. On an unknown date, the outcome of the inappropriate reconstitution technique was unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional details were reported as follows: This case was reported by a pharmacist. Age at vaccination was not reported. Pharmacist reported female patient received a dose of Boostrix that was not shaken vigorously to obtain a homogeneous, turbid, white suspension, which led to inappropriate reconstitution technique. Consented to follow up.